Karen Fancher, PharmD, BCOP, associate professor of pharmacy practice at Duquesne University and clinical oncology specialist ...
Site-neutral payment has advanced from E&M to drug administration codes, but stakeholders warn rapid, simultaneous policy ...
A pragmatic cluster-randomized trial across 8 CHC sites (Boston and Los Angeles) enrolled 5127 adults aged 45–75 years overdue for screening, randomizing clinics to FIT versus FIT-DNA outreach.
Advanced therapies are pressuring reimbursement and necessitating real-world durability data and new payment models, said ...
Specialty pharmacy workflows must account for longer, more complex affordability calls, with copay-shock interactions ...
Innovations in pharmacy are already delivering results, but there is still work to do to evolve the ecosystem, said Ryan ...
Rose Gerber, MS, director of patient advocacy and education at the Community Oncology Alliance (COA) Patient Advocacy Network ...
Randomized assignment to trabeculectomy versus drops enabled comparative assessment of visual field, IOP, and ...
Part B negotiations introduce buy-and-bill economics, ASP and 340B interactions, and heightened risk of non-medical switching ...
Lekan Ajayi, PharmD, explains how remote therapy monitoring keeps patients with cancer on track with their care and reduces ...
For Diana Verrilli, MS, senior vice president and general manager of Navista, the Community Oncology Alliance’s newly ...
Flatiron EHR-derived data from >220 community practices (~40% of US community oncologists) were analyzed for de novo stage IV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results